Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602363 · ClinicalTrials.gov registry record · Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
A Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Carna Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 13
- Study locations
NCT05602363 is a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Carna Biosciences. The registered enrollment target is 120 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (34% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT05602363, a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Carna Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Conditions Studied
Interventions
- DRUG Docirbrutinib
Study Locations (13)
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Moffitt Cancer Center - Tampa
Texas
- Oncology Consultants - Houston
- University of Texas MD Anderson Cancer Center - Houston
California
- UC Irvine Health - Orange
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- American Oncology Partners - Fort Wayne
Maryland
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center - Baltimore
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
New York
- Optum Medical Care PC - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602363
The ClinicalTrials.gov registry entry for NCT05602363 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (34% lower). The listed sponsor is Carna Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Docirbrutinib is the first listed.
NCT05602363 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05602363 about?
NCT05602363 is a clinical study titled "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma". This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
What is the current status of trial NCT05602363?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-08-01. Estimated completion is 2027-09.
What conditions does trial NCT05602363 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05602363?
The interventions under investigation include: Docirbrutinib (DRUG).
Who is sponsoring clinical trial NCT05602363?
This trial is sponsored by Carna Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05602363 being conducted?
This trial has 13 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.